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Abstract 
Introduction: With smoking restrictions becoming increasingly common in the United 
States, alternative tobacco products are being introduced that can be used discreetly 
when smoking is not permitted.   Many of these are smokeless tobacco products that do 
not require spitting and therefore may be more socially acceptable to use than the older 
smokeless products.  There is currently limited information regarding the extent to 
which these products deliver nicotine or the effect that they have on nicotine craving 
and withdrawal symptoms 
Methods:  Eleven smokeless tobacco users completed three laboratory sessions in this 
cross-over study.  At each session, they used either Camel Snus, Taboka or nicotine 
lozenge for a 30 minute period.  Nicotine concentrations were measured over a 90 
minute period and subjective measures (i.e. craving, withdrawal symptoms, product 
effects and liking measures) were assessed during product use and compared among 
products.      
Results:  Significant differences were found among products in maximal nicotine 
concentration (Cmax) and in the 90 minutes area under the concentration time curve 
(AUC90) (p<0.01 for both).  Both Cmax and AUC were highest when subjects received 
the nicotine lozenge.  AUC was significantly higher during medicinal nicotine use than 
during use of Camel Snus which was significantly higher than during us of Taboka.  
Cmax was significantly higher during use of nicotine lozenge and Camel Snus than 
during Taboka use.  No significant difference in time to reach maximal concentrations 
was observed among the three products.  The decline in craving and withdrawal 
symptoms during product use did not differ among products (no significant time x 
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product interaction) and few differences were seen among products on measures of 
product effects or liking.   
Conclusion:  The two smokeless tobacco products tested resulted in less nicotine 
exposure than use of medicinal nicotine.  These products had equivalent effects on 
craving and withdrawal symptoms and were equivalent on most measures assessing 
product effects and liking.  Since the newer tobacco products are rapidly changing and 
long term studies with each formulation of each product is not feasible, short term 
laboratory studies are needed to determine if and how smokers are likely to use these 
products and to determine if they offer any advantages (in terms of overall effects on 
public health) over medicinal nicotine products that lack the toxicants that all tobacco 
products contain.  The current study does not suggest that the products tested offer 
advantages over medicinal nicotine, however future studies are needed to determine if 
emerging products that contain higher nicotine levels are more effective at reducing 
craving and withdrawal symptoms or if they are more appealing to tobacco users based 
on other product characteristics.  Based on current data however, smokers who are 
interested in switching to less harmful products should be encouraged to use medicinal 
nicotine.   
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INTRODUCTION 
     With smoking restrictions becoming increasingly common in the United States, 
alternative tobacco products are being introduced that can be used discreetly when 
smoking is not permitted.  A variety of alternative tobacco products have been 
introduced, many of which are oral tobacco products which do not necessitate spitting 
like the older oral tobacco products did (Hatsukami et al., 2007).   Some of these 
products are packaged in pouches which are placed in the mouth and then discarded (with 
no spitting necessary while being used) whereas others dissolve in the mouth over time.  
Many of these products are available in a variety of flavors in order to further increase 
palatability for smokers that would normally not be interested in using smokeless tobacco 
products.  These products have been broadly referred to as either “potential reduced 
tobacco products” (PREPs) or potential modified risk tobacco products.   
     The advertising for these newer smokeless, spitless tobacco products had initially been 
largely targeted at smokers looking for an alternative to smoking when in a smoke-free 
environment.  For example, advertising for one of these products (i.e. Camel Snus) has 
used phrases such as “enjoy it anytime, anywhere”, “pleasure for wherever”, “No 
smoking? No problem” and “can be enjoyed virtually anywhere including places where 
smoking is banned or restricted” (Camel, 2010; Mejia and Ling, 2010; Samet and Wipfli, 
2009; Timberlake et al., 2011).  Indeed, a paper analyzing tobacco company documents 
concludes that these products were introduced as a cigarette alternative in response to 
indoor smoking restrictions (Mejia and Ling, 2010) and this message is being 
successfully disseminated to smokers as indicated by an analysis of comments on the 
Camel Snus discussion board which found that smokers frequently thought the product 
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was great for use in places or situations in which they could not smoke (Wackowski et 
al., 2011). Over time however, advertising has shifted to also target smokers interested in 
switching from cigarettes to one of these newer products.  More recent advertising for 
Camel Snus has incorporated phrases such as “Tune in, Smoke out” with some 
advertising appearing to be targeted at smokers who are likely interested in quitting 
smoking.  For example, seasonal promotional materials were used around the New Year 
in which Camel Snus was advertised as a way to maintain a “smoke-free resolution” 
(Trinkets and Trash, 2012).   The marketing for these newer products is therefore 
targeting a broad range of smokers likely resulting in the number of smokers using these 
products to increase over time.  Indeed, recent data suggests that a substantial number of 
smokers have heard of and tried these products.  In the areas where these products were 
first test-marketed, the number of smokers who have tried these products is substantial.  
In the part of Indiana in which most smokers were aware of these newer products, 20% of 
male smokers had reported trying either Taboka or Camel Snus (two of the products 
tested in the area) (Biener and Bogen, 2009) and 29% of young adult male smokers had 
tried snus in three additional test markets (Portland, Kansas City, Columbus) for snus 
products (Biener et al., 2011).  National survey data demonstrates that these products are 
becoming increasingly known and used.  A national survey of adults conducted in 2009 
found that 44.2% of adults had heard of Camel or Marlboro snus and 5.4% had tried one 
of these products (Regan et al., 2012).  Another survey similarly found that 5.1% of 
adults in the United States and 2.7% of adults in the US who have never smoked have 
tried Snus (McMillen et al., 2012).  Of particular concern is that adolescents and young 
adults are especially likely to be familiar with these products.  In the three test markets 
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for snus products described above, the rates of those who tried snus was highest in males 
between the ages of 18 and 24 (29%) and lowest in females over the age of 36 (1.1%).  
National surveys have reported that 61.9% of those between the ages of 18 and 24 had 
heard of and 8.0% have tried snus (McMillen et al., 2012; Regan et al., 2012).  A survey 
conducted among Texas students attending 6th to 12th grades found that 7.1% reported 
ever trying snus (Loukas et al., 2012).  
     The use of smokeless tobacco products may further be impacted by the suggestion by 
some that smokeless tobacco should be a recommended alternative for cigarette smoking 
since it is a less harmful tobacco product than cigarettes (Rodu, 1994; Rodu and 
Godshall, 2006; Russell et al., 1980; Russell et al., 1981).  Smokeless tobacco lacks the 
toxicants associated with combustion and data suggest that for the individual tobacco 
user, smokeless tobacco use is associated with lower risk of disease development (e.g. 
lung disease, cardiovascular disease) compared with continued smoking (Hatsukami et 
al., 2007).  Indeed there is evidence, both from studies in which the amount of toxicants 
is measured in the smokeless tobacco product and from studies in which amount of 
toxicants are measured in tobacco users who are asked to use these products exclusively 
for a period of time, that the level of toxicants (specifically tobacco specific nitrosamines) 
is lower in these newer smokeless products when compared to either cigarettes or 
traditional moist snuff (Blank and Eissenberg, 2010; Gray et al., 2008; Kotlyar et al., 
2011; Sarkar et al., 2010; Stepanov et al., 2006; Stepanov et al., 2008).  There is however 
significant controversy regarding using smokeless tobacco products in this manner since 
it is not known how promotion of such use will affect concurrent tobacco smoking in the 
individual or overall tobacco use at the population level.  For example, it is not known if 
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by attempting to switch from cigarettes to smokeless products, smokers would be less 
likely to quit tobacco products entirely or would ultimately be more likely to use both 
cigarettes and smokeless tobacco products (i.e. dual-use).  Furthermore, it is not known 
what effect promotion of smokeless tobacco products as less dangerous than cigarettes 
would have on tobacco use initiation, particularly given survey data suggesting that 
adolescents and young adults are the most likely groups to use these products.   
     The increased prevalence of smoking bans in public places, the development of 
smokeless tobacco products that can be used discreetly, the increasing marketing of these 
products to smokers and the promotion by some of smokeless tobacco as a safer 
alternative to continued smoking will all likely lead to a large number of smokers who 
are not interested in quitting to use these newer smokeless, spitless tobacco products.  
Current users of smokeless tobacco products are also likely to be interested in switching 
to a product that is more socially acceptable (since these newer products do not require 
spitting).  Additionally, there is increasing interest in investigating if newer smokeless 
tobacco products can be used as a means to facilitate cessation by those who are 
interested in quitting tobacco use entirely with a recent study finding that point 
prevalence quit rates 6 weeks after cessation were higher in those receiving snus than in 
those receiving placebo (18.4% vs. 8.8%) (Fagerstrom et al., 2012).  If there is continued 
interest in using these products as aids to smoking cessation, that would suggest that the 
population of tobacco users potentially using these products would include current users 
of traditional smokeless tobacco products, smokers who are not interested in quitting 
tobacco products as well as smokers who are interested in cessation.   
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     Despite the demonstrated increases in use of these products over the recent years and 
the potential for that increase to continue, there is relatively little information currently 
available about these products.  Basic information such as the extent of nicotine exposure 
following use of these products and the effect of these products on severity of craving 
and withdrawal symptoms are lacking.  Such information is necessary to determine the 
extent to which increased use of these products might maintain nicotine addiction and 
impact smoking behavior.  In a recent report from the Institute of Medicine “Scientific 
Standards for Studies on Modified Risk Tobacco Products”, among the twelve 
recommendations made is a call for studies assessing the effect of these newer products 
on addiction potential and on perception about the products’ effects and likelihood of 
addiction (Institute of Medicine, 2012).   
     The purpose of this study was to assess nicotine exposure and subjective responses of 
tobacco users when using one of two smokeless, spitless tobacco products and compare 
them to the medicinal nicotine lozenge (4 mg Commit).  The newer smokeless tobacco 
products studied were 1) Camel Snus (produced by RJ Reynolds) and Taboka (previously 
produced by Phillip Morris but no longer on the market).  These products are pasteurized 
rather than fermented, leading to lower concentrations of the tobacco specific 
nitrosamines that have been found to be associated with cancer risk.  These two specific 
products were chosen because they have substantially different amounts of nicotine and 
therefore could be expected to have different effects on subjective measures.  A study 
analyzing the amount of nicotine in these products reported that Taboka had 0.171 mg 
free nicotine per pouch whereas Camel Snus had 1.35 mg free nicotine per pouch 
(Stepanov et al., 2008).  This study assessing nicotine exposure after a single dose was 
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done in parallel with a study evaluating the use of these products on tobacco specific 
nitrosamines and withdrawal symptoms when used as a substitute for cigarettes in 
subjects interested in cessation (Kotlyar et al., 2011) .  The data from this single dose 
study can therefore help inform the interpretation of the results obtained in that cigarette 
switching study.  
 
METHODS 
Study Design 
     A randomized cross-over study was conducted in which subjects at each laboratory 
session received either one pouch of Taboka, one pouch of Camel Snus or a 4 mg 
nicotine lozenge.  Only current smokeless tobacco users were enrolled in order to collect 
information regarding product liking from a population that is familiar with these 
products.  The order in which subjects received products was random and laboratory 
sessions were separated by at least 3 days.  At each laboratory session nicotine 
concentrations were measured over a 90 minute period which included 30 minutes of 
product use and the 60 minute period following product use.  Measures of craving, 
withdrawal, product effects and product liking were measured during and immediately 
after use of each product.        
 
Subjects 
     Participants were recruited from the University of Minnesota and surrounding 
communities through flyers and advertisements in local media.  Eligible subjects were 
those that were between the ages of 18 and 65 and were daily users of traditional 
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smokeless tobacco products for at least one year.    Subjects were excluded if they 
reported any unstable medical or psychiatric conditions, were regularly using other 
tobacco products, had severe periodontal or other lesions or for other reasons that in the 
investigators’ judgment could interfere with measures being assessed.  The study was 
approved by the University of Minnesota Institutional Review Board and written 
informed consent was obtained from all subjects. 
 
Laboratory sessions 
     Blood was drawn immediately prior to and at 1, 2.5, 5, 7.5, 10, 15, 20, 25, 30, 45, 60, 
75 and 90 min after product placement with blood samples assayed for plasma nicotine 
concentrations.  Subjects were instructed to refrain from using any tobacco products for 
at least 12 hours prior to each laboratory session and an additional 2 hours elapsed 
between the subjects’ arrival and baseline measures to assure at least that length of 
abstinence.  An indwelling catheter (to facilitate blood draws) was placed thirty minutes 
prior to product use.   
     Subjects completed baseline questionnaires, were then provided the study product 
which they were to use for 30 minutes after which the product was removed and subjects 
rinsed their mouths with water.  Questionnaires assessing craving, withdrawal, product 
effects and liking were completed prior to product placement, 5 minutes and 15 minutes 
after product placement and immediately after the product was removed (i.e. 30 minutes 
after product placement).  To assess craving and withdrawal, a modified version of the 
Minnesota Nicotine Withdrawal Scale was used.  In this scale craving is determined via a 
single item on the scale, whereas withdrawal is determined by adding the scores of the 
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other 6 symptoms assessed (irritability/frustration/anger, anxiety/tension, difficulty 
concentrating, restlessness, depressed or sad mood and impatience).  This scale has been 
widely used to assess craving and withdrawal after the use of cigarettes (Hatsukami et al., 
1991; Hughes and Hatsukami, 1986; Hughes et al., 1991), medicinal nicotine (Hatsukami 
et al., 1992; Hatsukami et al., 1993) and smokeless tobacco products (including reduced 
exposure products) (Hatsukami et al., 1987; Hatsukami et al., 1992; Kotlyar et al., 2007).   
     To assess products effects and liking, a 17 item questionnaire was used on which 
subjects rated each item on a 10 point scale.  Items assessed the extent to which subjects 
1) craved tobacco; 2) felt good effects from the product; 3) felt bad effects from the 
product; 4) found the product satisfying; 5) liked the product; 6) desired the product; 7) 
felt the product was strong.  Additional items assessed the extent to which the product 
made subjects feel 8) good; 9) relaxed; 10) a head rush; 11) fast pounding heart; 12) 
tremor in hands, arms or face; 13) lightheaded / dizzy; 14) drowsy; 15) energetic; 16) 
jittery and 17) high.  This scale was adapted from scales previously described (Hasenfratz 
et al., 1993; Jaffe and Glaros, 1986; Kochhar and Warburton, 1990; Pritchard et al., 
1996; Schuh et al., 2001) and has been used in a previous study assessing smokeless 
tobacco products (Kotlyar et al., 2007). 
       
Pharmacokinetic Analysis 
     Because six of the eleven subjects had quantifiable baseline (i.e. time 0) nicotine 
concentrations (suggesting that they did not abstain from using tobacco products as 
directed), the measured concentrations were adjusted using the following equation: 
KteCCtadjCt  0)(  
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Where Ct(adj) is the adjusted plasma concentration used for purposes of analysis; Ct is 
the observed plasma concentration (or one-half the lower limit of quantitation if 
concentrations were too low to be quantified); C0 is the measured baseline plasma 
concentration (if the baseline was below the lower limit of quantitation, a value of 0 was 
substituted); K is the nicotine elimination rate constant of (0.693/120); and t is the time of 
the measured plasma concentration in minutes.  The half-life used for the calculation of 
the elimination rate constant (i.e. 120 minutes) is based on previous reports of average 
nicotine elimination half-life (Benowitz et al., 2006).  This approach to adjusting nicotine 
concentrations has been used in previous studies (Shiffman et al., 2009).   In three 
instances, a baseline plasma concentration was not available.  In those instances, the 
nicotine plasma concentration measured at 1 minute was used in the equation above for 
C0.  Adjusted nicotine concentrations were used to calculate each subject’s area under the 
concentration-time curve during the sampling period (AUC0-90), time to maximal 
concentration (Tmax) and maximal concentration observed (Cmax).  AUC was calculated 
using noncompartmental methods (WinNonlin Professional, Pharmsight Corporation, 
Mountain View, CA).   
 
Statistical Analysis 
The three pharmacokinetic parameters were analyzed in the natural logarithmic scale and 
were reported as geometric means adjusted for the session the product was given at.  
Linear mixed models with random subject effects were used to determine differences in 
AUC, Cmax and Tmax between the three products (Commit, Camel Snus and Taboka).  
The subjective effects included craving, withdrawal and items on the effects and liking 
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questionnaire.  To assess differences between products, the score for each response was 
analyzed with a linear mixed model with random subject effect and a repeated factor for 
time (0, 5, 15 and 30 minutes).  Baseline values for craving and withdrawal were added 
as covariates.  Interaction terms were included in the models if significant.   
All statistical analyses were performed using SAS, version 9.3 (SAS Institute).  P-values 
less than 0.05 were considered statistically significant.  The Tukey method was used to 
adjust p-values for pair-wise comparison. 
  
RESULTS 
Subjects 
     Eleven subjects completed three laboratory session (i.e. used each of the products 
during the study) and were included in the analysis.  All of the subjects were male.  The 
average age of subjects was 34 (range: 20 - 51).  Subjects on average used 4 tins of 
smokeless tobacco per week.   
 
Nicotine pharmacokinetics 
     The nicotine concentration-time profile for each of the three products is illustrated in 
Figure 1.    Significant differences among products were observed in the Cmax and in the 
90 minute AUC (table 1) (p<0.001 for both).  Both Cmax and AUC were highest when 
subjects received the nicotine lozenge.  AUC was significantly higher during medicinal 
nicotine use than during use of Camel Snus which was significantly higher than during us 
of Taboka.  Cmax was significantly higher during nicotine lozenge and Camel Snus use 
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than during Taboka use.  No significant difference in time to reach maximal 
concentrations was observed among the three products (figure 1).   
Table 1:  Nicotine AUC0-90 and Cmax for three products tested 
 Nicotine Lozenge (4mg) Camel Snus Taboka 
AUC (ng*min/ml) 397.38a
(264.12, 597.89) 
248.49b
(163.43, 377.81) 
153.30c 
(101.88, 230.65) 
Cmax (ng/ml) 6.97a
(5.05, 9.63) 
4.83a
(3.47, 6.73) 
2.90b 
(2.10, 4.00) 
Data are adjusted geometric mean (95% confidence interval).  Products with different letters were significantly different 
(p<0.05). 
 
Figure 1: Mean (+ SE) nicotine concentrations during and after 30 minutes use of three 
smokeless products 
 
Subjective Effects 
     The time course of craving and withdrawal symptoms reported during the 30 minute 
period that the products were being used are illustrated in figures 2 and 3.  There was a 
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main effect of time for both craving (p<0.002) and withdrawal (p=0.008) indicating that 
these symptoms declined during products use.  There was however no time x product 
interaction for either craving or withdrawal indicating that there was no difference 
between products in the decline of withdrawal symptoms.  Baseline values were not 
significantly different between products. 
     Among the items assessed on the drug effects and liking questionnaire, differences 
between products were found only in responses to how satisfying the product was and the 
extent to which the product made the subject feel energetic.  The adjusted mean score for 
satisfaction was higher for Snus than for either Taboka (p=0.016) or medicinal nicotine 
(p=0.018).  The score for feeling energetic was lower for Taboka than for either Snus 
(p<0.001) or medicinal nicotine (p<0.001).   
 
Figure 2: Mean craving score during use of three smokeless products 
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Figure 3: Mean withdrawal scores during use of three smokeless products 
 
DISCUSSION 
     This study found that when compared to medicinal nicotine, the two smokeless, 
spitless tobacco products tested achieved lower nicotine exposure and had very similar 
effects on measures of craving and withdrawal.  The products were similar in most 
measures on a product effect and liking scale, however Camel Snus had the highest 
ratings on a measure assessing how satisfying the product was and Taboka had the lowest 
scores on a measure assessing the extent to which subjects felt energetic.   
     This study adds to a growing body of literature examining the amount of nicotine that 
these products deliver and the effect they have on craving and withdrawal symptoms as 
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well as measures of product effects and liking.  This information from single dose studies 
is needed in order to determine how these products are likely to be used once in the 
marketplace.  Since nicotine is the primary addictive component in tobacco, the amount 
of nicotine that a new product delivers is likely to be a factor in how the product will be 
used.  Products with low levels of nicotine should be less likely to be acceptable 
substitutes to tobacco users in place of their usual brands since they would not replace the 
nicotine from the tobacco products that they are currently using.  Indeed, the current data 
demonstrates that Taboka delivered less nicotine than either Camel Snus or medicinal 
nicotine and a clinical study in which smokers were asked to substitute one of these 
products for their usual brand of cigarettes found that those assigned to Taboka used 
fewer doses (and smoked more cigarettes) than those assigned to either of the other two 
products (Kotlyar et al., 2011).  However, other product specific factors are likely to also 
contribute to how acceptable subjects find a particular product.  For example, in a study 
in which smokers were asked to sample and then select one of five products (i.e. Camel 
Snus, Marlboro Snus, General Snus, Stonewall, Ariva) to use during a 2 week cigarette 
abstinence period, no smokers selected General Snus despite it being the highest nicotine 
product available to choose from (Hatsukami et al., 2011).  Among the four products that 
were selected by smokers for the abstinence phase of the study, those who selected 
Camel Snus (the highest nicotine content product of the four) tended to use more of the 
product and to smoke fewer cigarettes than those who selected one of the other products 
(Hatsukami et al., 2011).  It therefore appears likely that nicotine content as well as other 
product characteristics influence how a product is likely to be used.  An analysis 
assessing the various components of the product effects and liking scale found that 
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measures of satisfaction are most associated with amount of the product that is used 
(Hatsukami et al., In Press).  In our study, Camel Snus was associated with the highest 
measures of satisfaction.   
     A limitation of any study examining specific tobacco products is that they are 
frequently being introduced, withdrawn or reformulated.  The Camel Snus that was used 
in the current study has since been reformulated into larger pouches and Taboka is no 
longer on the market.  Additionally, there may also be regional differences in the 
composition of these products.  For example, a study that evaluated the nicotine content 
in 36 samples of Camel Snus obtained from 5 different regions of the country found that 
there was an approximately 3 fold difference in unprotonated nicotine content (the 
biologically available form of nicotine) between products obtained in the regions with the 
highest nicotine content (i.e. west, south) relative to the region from which the products 
contained the lowest level of unprotonated nicotine (i.e. pacific northwest) (Stepanov et 
al., 2012).  Nonetheless, other studies examining nicotine concentrations achieved after 
use of these newer products have similarly found that for the products evaluated to date 
the maximal nicotine concentrations achieved after use are not generally higher than 
obtained from medicinal nicotine products such as nicotine gum and nicotine lozenge.  
For example, a study evaluating nicotine concentrations after use of two dissolvable 
products (i.e. Ariva, Stonewall) or a tobacco pouch product (i.e. Revel) found that 
maximal nicotine concentration obtained after the use of any of these three products was 
lower than after the use of the medicinal nicotine lozenge (Kotlyar et al., 2007).   A study 
that evaluated nicotine concentrations after use of a single dose of Ariva found similarly 
modest increases in nicotine concentrations (Blank and Eissenberg, 2010).   A study in 
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which smokers used 2 doses (separated by 60 minutes) of three non-combustible products 
(i.e. Ariva, Camel Snus original flavor, Marlboro Snus mild flavor) and the 2 mg nicotine 
lozenge found that 15 minutes after the administration of the second dose only Camel 
Snus had significantly higher plasma nicotine concentrations relative to baseline (mean 
plasma concentration of 7.6 ng/ml).  The increase in plasma concentration was next 
highest for those receiving nicotine lozenge (mean concentration of 4.6 ng/ml), followed 
by Ariva (mean concentration of 3.4 ng/ml) and Marlboro Snus (mean concentration of 
2.9 ng/ml).  Since the nicotine lozenge dose used was one-half of that used in our study 
(2 mg vs. 4 mg), the results are consistent with our findings that nicotine concentrations 
after use of these newer products tested to date are no higher than after use of medicinal 
nicotine (Cobb et al., 2010).  These data are in contrast to studies with older smokeless 
tobacco products (e.g. moist snuff) that demonstrated higher peak concentrations after 
use of those products when compared to medicinal nicotine (Benowitz et al., 1988; 
Kotlyar et al., 2007).   
     Of importance when evaluating newer smokeless tobacco products is what effect they 
have on craving and withdrawal symptoms since this may impact how likely the products 
are to be used as a substitute for usual brand cigarettes or traditional smokeless tobacco 
products.  The products evaluated to date have generally found that medicinal nicotine 
and the newer products have comparable effects on nicotine craving and withdrawal 
symptoms, however the amount of nicotine that a product has does influence these 
measures.  In a study comparing 3 of the newer tobacco products to medicinal nicotine, 
craving levels were highest in the product that delivered the lowest amount of nicotine 
(i.e. Revel) (Kotlyar et al., 2007).  In the current study, no differences were found among 
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products despite the observed differences in nicotine concentrations.  There are several 
potential explanations for these findings.  It is possible that product characteristics other 
than nicotine delivery influence the effects that the product has on subjective symptoms.  
Indeed in the current study, Camel Snus was rated as a more satisfying product than 
nicotine lozenge despite lower nicotine exposure.  It is possible that these factors 
contributed to the lack of difference in craving and withdrawal symptoms score.  Another 
potential explanation is that compared to their regular smokeless tobacco use, subjects 
taking any of the three products received so little nicotine that there was no discernible 
difference between them in subjective measures (i.e. there is a nicotine floor effect below 
which there are no differences in response).  A third potential explanation is that the 
differences in nicotine concentrations seen between the products tested were not large 
enough to influence craving and withdrawal symptoms.  Future studies are needed to 
determine if any of these explanations is accurate.   
     Our study is nonetheless generally consistent with other studies showing that 
medicinal nicotine and the newer smokeless tobacco products have similar effects on 
craving and withdrawal symptoms.  A study comparing several products (including 
Camel Snus and nicotine lozenge) found similar effects of these products on urge to 
smoke (Cobb et al., 2010).  Although the Swedish Snus products are not very well 
accepted by smokers in the United States (Hatsukami et al., 2011), several studies with 
these products also demonstrate that snus products do not seem to have substantial 
benefits over medicinal nicotine in decreasing withdrawal symptoms.  For example, one 
study found both Swedish Snus and nicotine lozenges suppressed craving to a similar 
degree but that the lozenges suppressed craving for a longer time period (Barrett and 
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Wagner, 2011) and another study found that decreases in craving after use of either 
Swedish Snus or nicotine gum were equivalent (Lunell and Curvall, 2011).  A study in 
which smokers not interested in quitting were asked to sample nicotine lozenge, Camel 
Snus, Marlboro Snus and Stonewall (three newer smokeless products) for a week found 
that smokers preferred the nicotine lozenges over the other products (O'Connor et al., 
2011).  These studies demonstrate that medicinal nicotine delivers at least as much 
nicotine as the currently available newer smokeless products that have been tested, is as 
effective at reducing craving and withdrawal symptoms and may be preferred over the 
smokeless products.   
     Of particular importance when evaluating these tobacco products is the extent to 
which they expose smokers to toxicants associated with tobacco related disease.  
Medicinal nicotine results in no exposure to such toxicants whereas this is not the case of 
these newer tobacco products.  In a study in which smokers were asked to quit smoking 
and were given 4 weeks of either Camel Snus, Taboka or medicinal nicotine, 
concentrations of NNAL decreased to a greater extent in those using medicinal nicotine 
relative to those using Camel Snus suggesting a lower health risk for medicinal nicotine 
(Kotlyar et al., 2011).  Other published studies also suggest that although smokeless 
tobacco products are substantially safer than cigarette smoking, they are not harmless.  
Swedish moist snuff (i.e. snus) contains lower levels of carcinogens than most other 
brands of moist snuff but even these products have been found to contain nitrosamines 
(Hatsukami et al., 2004; Hatsukami et al., 2007) and use of these products has been 
associated with increased risk of pancreatic cancer (Boffetta et al., 2005; Luo et al., 
2007).  Some studies have suggested that use of Swedish Snus also may be associated 
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with a higher risk of oral or gastroesophageal cancer and fatal cardiovascular disease 
(particularly myocardial infarction) (Hergens et al., 2007; Roosaar et al., 2008; 
Zendehdel et al., 2008).  Therefore, use of these smokeless products should be 
recommended only if the health risk is lower than with continued smoking and there are 
no lower risk products available.  The current data does not suggest that this is the case 
since medicinal nicotine appears to be equally effective as the currently tested products 
on subjective effects of smoking without exposing tobacco users to additional toxicants.  
Efforts are needed to educate the public regarding the health risks associated with the 
various smokeless products relative to the risk associated with medicinal nicotine.  A 
survey of adults in which 22.1% indicated that they believe snus is as harmful as 
medicinal nicotine or non-nicotine medications and 51.9% were not sure if snus is more 
harmful than medicinal nicotine or non-nicotine medications suggests that smokers are 
currently lacking this information (Regan et al., 2012). 
       Despite no clearly demonstrated advantages of these smokeless products over 
medicinal nicotine, marketing efforts by tobacco companies will likely lead to them being 
used extensively by smokers (and perhaps non-smokers).  Although the health risks 
associated with smokeless tobacco use are lower than the health risks associated with 
cigarette smoking, risk to a smoker would only be lower if smokeless tobacco use doesn’t 
undermine tobacco abstinence.  To fully address this question, studies would need to be 
conducted in smokers interested in quitting as well as smokers not currently interested in 
quitting.  For those who are currently interested in quitting, the primary concern would be 
that rather than complete cessation, use of these products would result in smokers either 
switching to smokeless products or of greatest concern to concurrently use both the 
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smokeless tobacco product and cigarettes (i.e. dual use).  For those who are not currently 
interested in quitting, the primary concern is that use of smokeless tobacco products 
would decrease their future motivation to entirely quit tobacco use.  Few studies have 
addressed these issues.  A small study (n=31) found that 2 weeks of Ariva or Stonewall 
use (two of the newer smokeless tobacco products) in smokers not interested in quitting 
resulted in a significant increase in motivation to quit relative to continued smoking 
(Carpenter and Gray, 2010), however the study did not utilize a medicinal nicotine 
condition to determine if the same results could have been attained with medicinal 
nicotine nor did it follow smokers to determine if they had actually quit smoking.  Clearly 
more research is needed to determine the consequences that increased marketing of the 
newer smokeless tobacco products will have on smoking behavior in current smokers as 
well as on smoking uptake by adolescents and young adults.   
     There are a number of limitations to this study.  One limitation is that this study was 
conducted in users of traditional smokeless tobacco products rather than in cigarette 
smokers.  The study was designed in this manner in order to assess subjects who are 
already familiar with and comfortable using oral tobacco products but this makes it 
difficult to generalize these results to cigarette smokers who are likely to be the main 
users of these products.  It is unlikely that the nicotine concentration time profile after use 
of these products would be different in smokers than in users of smokeless tobacco 
products; therefore those data should be applicable to both populations.  It is less clear 
that the results obtained on the subjective measures are also applicable to smokers and a 
study directly comparing the effects of these products in smokers and smokeless tobacco 
users would be needed to confirm if they are applicable to both populations.  An 
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additional limitation is that based on baseline nicotine concentrations, a majority of 
smokers did not abstain from using tobacco products overnight prior to each laboratory 
session (despite being asked to do so).  A mathematical correction was applied to the 
observed nicotine concentrations to address this issue; however the calculation assumes 
that the elimination rate constant is the same for all subjects despite known variability 
that exists between individuals in rate of nicotine metabolism (Benowitz et al., 2006).  
Nevertheless, the adjusted values should result in a reasonable approximation of the 
nicotine concentration boost that occurred as a result of using the study product.  The 
effect of noncompliance with tobacco abstinence is potentially more problematic in 
interpreting the results of the subjective measures since these cannot be corrected for.  
Abstinence at baseline did not significantly predict craving and withdrawal scores 
although separating those who abstained from those who did not resulted in an extremely 
small sample size and therefore that analysis does not yield interpretable data.  The data 
on subjective effects is largely consistent with what was observed in other studies and 
with the nicotine concentration data, therefore although it should be interpreted with 
caution, it does add to the overall literature on the topic.   
     In summary, assessing pharmacokinetics of a product is an important component in 
evaluating tobacco products.  The current study found that nicotine exposure (as 
measured by the 90 minute nicotine AUC) was higher after medicinal nicotine use than 
after the use of either Camel Snus or Taboka.  Despite these differences in nicotine 
exposure, no differences were observed in craving and withdrawal symptoms and few 
differences were observed in measures of product effects and liking.  This suggests that 
the subjective measures are either influenced by product characteristics other than 
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nicotine delivery or that bigger differences in nicotine delivery are needed in order to 
influence these measures.  The factors that influence subjective response to tobacco 
products are important to determine as they are likely to be significant factors in how 
these products will be used by tobacco users.  This study is consistent with the literature 
in suggesting that the newer smokeless tobacco products tested several years ago, 
although higher in toxicants than medicinal nicotine tend not to be more effective in 
decreasing craving or withdrawal symptoms.  Unless data is generated suggesting that 
smokeless tobacco products offer some advantage over medicinal nicotine in decreasing 
overall tobacco related health risk, medicinal nicotine should be preferentially 
recommended for smokers looking for an alternative to their current tobacco product.  
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